Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial.
Nicolas Martinez-MajanderGeorge NtaiosY Y LiuP YlikotilaH JoensuuJ SaarinenK S PereraJ Marti-FabregasA ChamorroSalvatore RudilossoLuís Prats-SánchezS D BerkowitzH MundlE ThemelesM TiainenA DemchukS E KasnerR G HartT Tatlisumaknull nullPublished in: European journal of neurology (2020)
Our exploratory analyses show that patients with embolic stroke of undetermined source and a history of cancer had similar rates of recurrent ischaemic strokes and all-cause mortality during aspirin and rivaroxaban treatments and that aspirin appeared safer than rivaroxaban in cancer patients regarding major bleeds. www.clinicaltrials.gov (NCT02313909).
Keyphrases
- atrial fibrillation
- low dose
- venous thromboembolism
- antiplatelet therapy
- cardiovascular events
- pulmonary embolism
- percutaneous coronary intervention
- papillary thyroid
- anti inflammatory drugs
- cardiovascular disease
- clinical trial
- type diabetes
- lymph node metastasis
- brain injury
- childhood cancer
- study protocol
- subarachnoid hemorrhage